Can-Fite BioPharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CANF research report →
Range $8 – $8
Price Chart
About the company
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction.
- CEO
- Motti Farbstein
- IPO
- 2012
- Employees
- 5
- HQ
- Ramat Gan, IL
Get TickerSpark's AI analysis on CANF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.88M
- P/E
- -0.21
- Fwd P/E
- 20.50
- PEG
- 0.00
- P/S
- 7.73
- P/B
- 0.56
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2402.96%
- Net Margin
- -2358.77%
- ROE
- -182.89%
- ROIC
- -165.57%
Latest fiscal year · YoY change
- Revenue
- $408.21K-39.4%
- Gross Profit
- $384.02K-43.0%
- Op Income
- $-10,028,933
- Net Income
- $-9,905,965-25.7%
- EPS
- $-0.08-1013.9%
- OCF Growth
- -18.1%
- FCF Growth
- -18.1%
- 52W High
- $10.40
- 52W Low
- $1.42
- 50D MA
- $1.90
- 200D MA
- $3.03
- Beta
- 0.02
- RSI (14)
- 32
- Avg Volume
- 375.13K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Can-Fite reported encouraging psoriasis Phase III interim feedback, paused its rheumatoid arthritis program after missing the non-inferiority endpoint, and ended the quarter with $10.22 million in cash.· November 30, 2020
- Psoriasis Phase III: the independent committee recommended continuing the study and dropping one dose group based on positive interim data.
- Rheumatoid arthritis Phase III: the study will not continue after missing the primary non-inferiority endpoint versus methotrexate, even though efficacy was superior to placebo.
- COVID-19 Phase II: FDA and IRB clearance were received, with first patient enrollment expected before year-end.
- NASH remains a key focus: management highlighted promising Phase II data, a late-breaking AASLD oral presentation, and a new European patent.
- The company ended Q3 with $10.22 million in cash, helped by $17.68 million of net proceeds from financings earlier in 2020.
For the nine months ended September 30, 2020, revenue was $0.61 million versus $1.84 million a year ago. Research and development expenses were $9.05 million versus $7.01 million, general and administrative expenses were $2.14 million versus $2.22 million, and net financial expenses were $0.22 million versus $0.44 million. Net loss was $10.81 million compared with $7.84 million in the prior-year period. Cash and cash equivalents were $10.22 million at September 30, 2020, up from $2.69 million at December 31, 2019. Management said the psoriasis study should take about 10 to 12 months after the last patient is enrolled, and expects to begin COVID-19 enrollment by year-end, continue the psoriasis study in 2021, initiate a pivotal Phase III liver cancer study, and start the next NAFLD/NASH study.
CEO Pnina Fishman emphasized that the psoriasis interim result was highly encouraging because the IDMC recommended continuing the Phase III study and optimizing the dose by dropping one arm. She contrasted that with rheumatoid arthritis, where the study was stopped after failing the non-inferiority endpoint, but noted the drug still beat placebo on efficacy. Her tone was constructive and pipeline-focused, stressing future priorities in psoriasis, NASH, liver cancer, COVID-19, and even a new cannabis assay that could be monetized on a fee-for-service basis.
CFO Motti Farbstein reviewed the Q3 year-to-date financials and pointed to revenue of $0.61 million, down from $1.84 million, mainly because less of the advance payments from Gebro, CKD Pharmaceuticals, and Cipher was recognized. R&D rose to $9.05 million due mainly to Piclidenoson phase III enrollment costs, while G&A was broadly flat at $2.14 million and financial expenses declined to $0.22 million. He also said the RA study’s costs were between $5 million and $6 million at interim analysis, and explained the company’s $10.22 million cash balance as the result of $17.68 million in net financing proceeds offset by $10.16 million in operating cash use.
Analysts asked when the psoriasis study would finish and when a Phase III study for Namodenoson might start. Management said psoriasis enrollment should be completed in a couple of months, with data expected roughly 10 to 12 months after the last patient finishes treatment, while the next NASH study is still in the planning stage with key opinion leaders. Questions also focused on the RA study cost, the U.S. patent strategy for Namodenoson in NASH, the meaning of the cannabis assay’s fee-for-service model, and partnership activity; management said it would include the U.S. as progress advances, described the assay as a unique way to test cannabis-derived compounds for activity at the A3 receptor, and said partnership efforts are ongoing but details would come in future press releases.
The strongest bull case from the call is that psoriasis remains alive and may actually be optimized by the IDMC’s recommendation to drop one dose group, with management believing the study could finish sooner than planned. NASH and liver cancer remain active pipeline programs, the company has received regulatory clearance for a COVID-19 trial, and management expressed confidence that its oral, safety-oriented profile could support partnering and future commercialization.
The main bear case is that the rheumatoid arthritis program failed its primary endpoint and is being stopped, which highlights clinical risk in the platform. Revenue remains small and down year over year, losses continue, and the company is still dependent on financing activity to fund development. Even where progress exists, many programs are still in early or preparatory stages, so meaningful clinical and commercial risk remains.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.1%
- Shares Outstanding
- 1.31M
- Float Shares
- 121.77M
of shares held by institutions
16 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| American Portfolios Advisors | 1.10K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 26 | Farbstein Motti | other | 24,000 |
| Jun 4, 26 | Fishman Pnina | other | 24,000 |
| Apr 25, 26 | Tamir Ilan | other | 0 |
| Apr 25, 26 | Regev Guy | other | 0 |
| Aug 1, 23 | Regev Guy | other | 0 |
| Aug 7, 24 | Regev Guy | other | 0 |
| Jun 15, 20 | Regev Guy | other | 0 |
| Feb 8, 17 | Regev Guy | other | 0 |
| Mar 18, 26 | Regev Guy | other | 0 |
| Apr 25, 26 | Bornstein Yoseph | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CANF coverage
Recent articles, reports, and earnings notes.
No research on CANF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CANF report →Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
globenewswire.com · Nov 18
Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal
globenewswire.com · Nov 12
Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study
globenewswire.com · Nov 9
Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
globenewswire.com · Nov 6
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
globenewswire.com · Nov 2
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
globenewswire.com · Oct 26
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
globenewswire.com · Sep 9
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
globenewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.